New combo therapy for bile duct cancer enters safety trial

NCT ID NCT06274879

Recruiting now Disease control Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding a procedure called radiofrequency ablation (bRFA) to standard chemotherapy and immunotherapy is safe for people with bile duct cancer that cannot be removed by surgery. About 36 participants will be randomly assigned to receive either standard care (stent placement plus drugs) or standard care plus bRFA. The study will track serious side effects and treatment disruptions over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiofrequency ablation
What this could lead to: If successful, this could show that adding radiofrequency ablation to standard treatment is safe, potentially offering a new way to control bile duct cancer.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The procedure carries risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct cancer bile duct neoplasm extrahepatic bile duct carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILE DUCT CANCER

Contacts and locations

Locations

Hôpitaux Universitaires Genève
NOT_YET_RECRUITING

Geneva, 1205, Switzerland
Inselspital Bern University Hospital
RECRUITING

Bern, 3010, Switzerland
Luzerner Kantonspital
NOT_YET_RECRUITING

Lucerne, 6004, Switzerland
Universitätsspital Zürich
NOT_YET_RECRUITING

Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.